TLDR CRISPR/Cas9 gene-editing shows promise for improving sheep and goat breeding but faces challenges with efficiency and accuracy.
The document discusses the use of CRISPR-Cas9 gene-editing technology in the genetic improvement of livestock, specifically sheep and goats. The technology allows for precise modifications in DNA or RNA sequences at the genome level, improving genetic traits. However, it has limitations such as low efficiency in inserting foreign genes and off-target effects. Despite these, it remains the most effective gene-editing technology due to its low cost, simple operation, accurate editing, high efficiency, and ability to target multiple gene sites simultaneously. It has been used to enhance disease resistance, increase meat production, and improve cashmere growth in sheep and goats by increasing hair follicle density and length. The document also highlights ethical concerns related to the use of this technology, including the safety of gene-edited species and their by-products, the impact on biodiversity, and animal welfare. The authors conclude that with further research and development, CRISPR-Cas9 could revolutionize the genetic improvement of sheep and goats.
23 citations
,
May 2020 in “Cell Death and Disease” Blocking the FGF5 gene in sheep leads to more fine wool and active hair follicles due to changes in certain cell signaling pathways.
23 citations
,
March 2019 in “Gene” Editing the FGF5 gene in sheep increases wool length, confirming its role in hair growth.
17 citations
,
January 2019 in “International journal of biological sciences” Researchers used CRISPR/Cas9 to create a goat with a gene that increased cashmere production by 74.5% without affecting quality.
33 citations
,
January 2018 in “International Journal of Biological Sciences” CRISPR-Cas9 can successfully edit genes in large mammals like Cashmere goats.
7 citations
,
August 2022 in “Journal of Nanobiotechnology” Advancements in nanoformulations for CRISPR-Cas9 genome editing can respond to specific triggers for controlled gene editing, showing promise in treating incurable diseases, but challenges like precision and system design complexity still need to be addressed.
June 2022 in “Authorea (Authorea)” Efficient delivery systems are needed for the clinical use of CRISPR-Cas9 gene editing.
23 citations
,
January 2022 in “Biomaterials Science” Non-viral vectors show promise for safe and effective CRISPR/Cas9 gene editing in treating diseases.
June 2024 in “International Journal of Nanomedicine” CRISPR/Cas9 has improved precision and control but still faces clinical challenges.
1 citations
,
April 2023 in “International Journal of Molecular Sciences” New CRISPR/Cas9 variants and nanotechnology-based delivery methods are improving cancer treatment, but choosing the best variant and overcoming certain limitations remain challenges.
